← Eichor
Study identifier: NCT05621291 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

Condition: B-All · Acute Lymphoblastic Leukemia  ·  Sponsor: National Cancer Institute (NCI)

PhaseNA
Planned participants60
Who can joinAll sexes, 1 Year to 25 Years
Healthy volunteersNo

About this study

Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who achieve remission after CART alone, it may cure up to 50% of people who receive this therapy. However, for people who relapse after CART, it can be hard to achieve remission again. In patients where CART fails, stem cell transplant (HCT) can be used to prevent relapse and achieve cure. But HCT can cause serious side effects. Better testing is needed to distinguish people who can be cured with CART alone from people who may also need to have HCT. Objective: To see if the use of a series of blood and bone marrow tests at regular intervals can help monitor for B-ALL relapse after CART therapy. Eligibility: People aged 1 to 25 years with B-ALL who have had CART therapy within the past 42 days. They must never have had a blood stem cell transplant; they must also have no measurable blood cancer cells. Design: Participants will visit the clinic every 2 weeks starting 42 days after they receive CART therapy. Each visit will be about the same amount of time as a regular clinic visit. about 8 hours. Participants will have blood drawn for testing on each visit. Bone marrow biopsy/aspirate will be done during 4 of the visits at routine timepoints after CART. A needle will be inserted to draw a sample of tissue from inside the bone in the hip. A small amount of blood and tissue will be tested with ClonoSEQ and to evaluate fo…

This description comes directly from the study's public registry record.

Talk to the study team

NCI Ped LeukemiaLymph Cell Tx Tm  ·  (240) 760-6970  ·  ncilltct@mail.nih.gov

Alexandra Dreyzin, M.D.  ·  (301) 451-4801  ·  alexandra.dreyzin@nih.gov

Always discuss trial participation with your own doctor first.

Locations (8)

Children's Hospital of Los AngelesLos Angeles, California, United StatesRecruiting
Children's National Medical CenterWashington D.C., District of Columbia, United StatesRecruiting
Children's Healthcare of AtlantaAtlanta, Georgia, United StatesNot Yet Recruiting
National Institutes of Health Clinical CenterBethesda, Maryland, United StatesRecruiting
Dana-Farber/Boston Children s HospitalBoston, Massachusetts, United StatesNot Yet Recruiting
Huntsman Cancer Institute, University of UtahSalt Lake City, Utah, United StatesRecruiting
Seattle Children's, University of WashingtonSeattle, Washington, United StatesRecruiting
Fred Hutchinson Cancer Research CenterSeattle, Washington, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05621291